A recent study shows that work plays an active role in keeping our brains healthy. “We have demonstrated the role of working activity on cognitive performance”. Professor Raffaella Rumiati says … “Many studies have been focused on the factors influencing our brain aging and differences in cognitive decline have been often observed in association with education or other related to quality of life. From our analysis it emerges that the type of work activity also contributes to the differences in normal and pathological cognitive aging”. [Read more…] about Complex occupations help protect our brains from aging-related cognitive decline
The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging.
After initially indicating that Aduhelm could be prescribed to anyone with dementia, the Food and Drug Administration now specifies that the prescription drug be given to individuals with mild cognitive impairment or early-stage Alzheimer’s, the groups in which the medication was studied.
Yet this narrower recommendation raises questions. What does a diagnosis of mild cognitive impairment mean? Is Aduhelm appropriate for all people with mild cognitive impairment, or only some? And who should decide which patients qualify for treatment: dementia specialists or primary care physicians? [Read more…] about Six guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease
How do genetics impact early intervention for dementia? (Medical News Bulletin):
“Cardiovascular and neurological diseases, such as dementia, have been linked to dysfunction of a variation of the apolipoprotein E, or APOE, gene, called the APOE e4 allele…The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) evaluated whether the effectiveness of lifestyle modifications for those at risk of Alzheimer’s disease would be different for those with or without the APOE e4 gene. [Read more…] about Cognitive training, diet, exercise, and vascular management seen to improve cognition even in people with genetic predisposition for dementia (APOE e4)
“Geek researchers demonstrated the potential of a virtual supermarket cognitive training game as a screening tool for patients with mild cognitive impairment (MCI) among a sample of older adults…
In an article published in the Journal of Alzheimer’s Disease, the researchers [Read more…] about Study: Harnessing a virtual reality brain training game to diagnose mild cognitive impairment (MCI)
Ruth Frances Keir runs Cambridge Cognition (AIM: COG), one of the 10 Companies to Watch in 2013/ 2014 according to our latest market report, which develops and commercializes computerised neuropsychological tests used in a variety of healthcare and research settings. She joined the Cambridge Cognition board initially in 2010 as a non-executive director, bringing to it more than 26 years’ experience in research and business development positions in the pharmaceutical industry, as well as a period as Director of her own consultancy business, Archea Ltd.
–> To Learn More and Register, click on 2013 SharpBrains Virtual Summit: September 19–20th, 2013
Cambridge Cognition, one of the 10 Companies to Watch in 2013/ 2014 according to our latest market report, just announced its plans to go public in the UK’s AIM market.
Cambridge Cognition in £15M AIM IPO (Business Weekly): “… the move will [Read more…] about Cambridge Cognition, developer of computerised neuropsychological tests, to go public in the UK